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Edited by Lev KisselevAbstract Mitochondrial lysyl-tRNA synthetase (LysRS) is
thought to be involved in the speciﬁc packaging of tRNALys3 into
HIV-1 viral particles. The HIV-1 auxiliary viral protein Vpr is
an apoptogenic protein that aﬀects the integrity of the mitochon-
drial membrane and has also been reported to interact with
LysRS. In the present study, we show that HIV-1 Vpr expressed
in E. coli and puriﬁed to homogeneity does not interact speciﬁ-
cally with LysRS and does not impact its aminoacylation activ-
ity. However, we also show that the mitochondrial localization of
LysRS in HeLa cells is altered after addition of Vpr in the cul-
ture medium. These results suggest that HIV-1 Vpr fulﬁlls an
essential role in the process of packaging of mitochondrial
LysRS.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mitochondria1. Introduction
The HIV-1 viral protein Vpr is a 96 amino acid residue pro-
tein produced during the late phases of HIV-1 infection. Vpr is
a nucleocytoplasmic shuttling protein [1] that has been in-
volved in several cellular processes including nuclear uptake
of the viral preintegration complex, cell cycle arrest and apop-
tosis, and may have distinct roles along the viral life cycle [2,3].
It is packaged into the virions through an interaction with the
p6 region of Gag [4].
HIV-1 Vpr is believed to contribute multiple cytopathic ef-
fects. Among the putative functions of Vpr, this 14 kDa
HIV-1 accessory protein has been described as a potent apop-
togenic protein [5–9]. When added to isolated mitochondria, it
has been shown that Vpr acts on the permeability transition
pore complex. It induces dissipation of the inner mitochondrial*Corresponding author. Fax: + 33 1 69 82 31 29.
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doi:10.1016/j.febslet.2007.05.076transmembrane potential and the release of cytochrome c [10].
It is also worth noting that Vpr is a natural transducing pro-
tein that may be eﬀectively taken up from the extracellular
medium, and thus can aﬀect bystander uninfected cells [11–13].
Initiation of reverse transcription of the HIV-1 RNA gen-
ome requires host cell tRNALys3 as a RNA primer. This tRNA
is incorporated into HIV-1 particles [14] along with the mito-
chondrial species of lysyl-tRNA synthetase (LysRS) [15] that
might serve as a carrier for the selective packaging of lysine-
speciﬁc isoacceptor tRNAs. The molecular mechanisms and
the viral proteins involved in the selective capture of LysRS
into the virions, and thus in the selective packaging of the
RNA primer necessary to initiate replication, are not well
understood. One of the current model for the selective packag-
ing of the LysRS:tRNALys complex involves the formation of
a packaging complex with the two viral proteins Gag and Gag-
Pol [16]. In addition, the viral protein Vpr has been reported to
interact with LysRS [17] and thus might also be involved in its
sorting into the viral particles. Further, Vpr-induced apoptosis
alters the permeability of the mitochondrial membrane and
thus might either impair the mitochondrial import of the
LysRS precursor bearing the mitochondrial targeting peptide,
or induce the release of mature mitochondrial LysRS. These
ﬁndings have led us to analyze the eﬀect of puriﬁed recombi-
nant Vpr on the in vitro activity of LysRS and on its cellular
localization.2. Materials and methods
2.1. Antibodies and Western blot analysis
Antibodies directed to Vpr were a gift from Dr. Uwe Tessmer.
Monoclonal antibodies to PARP were from BD Biosciences. Poly-
clonal anti-LysRS [18], anti-mitochondrial LysRS [15] and anti-p43
[19] antibodies have been described previously. Western blot analyses
were conducted with goat anti-rabbit or goat anti-mouse secondary
antibodies conjugated with peroxidase (Chemicon) and the ECL detec-
tion reagents (Amersham Biosciences).2.2. Puriﬁcation of GST-Vpr fusion protein
Vpr was expressed from the pGEX/Vpr plasmid (gift from F. Bach-
elerie, Institut Pasteur, Paris). Puriﬁcation of the GST-Vpr fusion pro-
tein was performed starting from a 2 l culture of XL1-Blue
transformed by pGEX/Vpr and grown at 37 C in LB-ampicilin
(25 lg/ml) broth to a cell density corresponding to A600 = 0.75. At that
time, temperature was adjusted to 28 C. After 15 min at 28 C, the re-
combinant protein was expressed for 2–3 h by addition of 1 mM IPTG.
All subsequent steps were conducted at 4 C. Cells were harvested by
centrifugation (6000 · g for 10 min), washed with ice-cold extraction
buﬀer (20 mM Tris–HCl, pH 8.0, 150 mM NaCl, 10 mM EDTA,
10% glycerol, 0.2% NP40, 0.5% DOC and 1 mM 2-mercaptoethanol),blished by Elsevier B.V. All rights reserved.
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diisopropylﬂuorophosphate (DFP) and homogenized with an Eaton
press. After lysis, the supernatant was diluted with 25 ml of extraction
buﬀer containing 1 mM DFP, sonicated to fragment nucleic acids and
clariﬁed by centrifugation at 25000 · g for 30 min. The lysate was
loaded on a 3 ml Glutathione Sepharose 4B matrix (GE Healthcare,
1.6 · 1.5 cm). After washing with 100 mM Tris–HCl, pH 8.0,
250 mM NaCl, 10 mM EDTA, 10% glycerol, 0.2% NP40, and 0.5%
DOC, bound material was eluted by a step gradient of the same buﬀer
containing 20 mM reduced glutathione. Fractions containing Vpr were
pooled, dialyzed against 50 mM Tris–HCl, pH 8.0, 150 mM NaCl,
1 mM EDTA, 10% glycerol, 0.2% NP40, 0.5% DOC and 2 mM dithi-
othreitol (DTT). This fraction was applied to a 0.64 · 3.0 cm column
of SOURCE 15Q (GE Healthcare) equilibrated in the same buﬀer.
The GST-Vpr protein was eluted by a 40 ml linear gradient of NaCl
from 150 to 500 mM in the same buﬀer. Fractions containing GST-
Vpr (eluted at 310 mM) were pooled, dialyzed against 50 mM Tris–
HCl, pH 8.0, 50 mM NaCl, 2 mM EDTA, 2 mM DTT, 55% glycerol,
and stored at 20 C at a protein concentration of 4 mg/ml. Protein
concentration was determined by using a calculated absorption coeﬃ-
cient of 1.752 A280 units mg
1 cm2.
2.3. Vpr-induced apoptosis
The human promonocytic cell line U937 (American Type Culture
Collection) was grown in RPMI medium supplemented with 10%
FCS, 2 mM glutamine, 100 lg/ml of penicillin and streptomycin, and
induced to undergo apoptosis by addition of recombinant Vpr at
17 nM. Development of apoptosis was assessed by PARP cleavage.
Cell survival was determined by the MTT assay (Sigma) and cell death
by the trypan blue (0.05%) exclusion assay. At the times indicated, to-
tal extracts were prepared and analyzed by Western blotting using anti-
PARP, anti-p43 or anti-LysRS antibodies. Mitochondria were isolated
from U937 cells as described previously, and the absence of cytoplas-
mic contamination was assessed by probing the mitochondrial prepa-
ration with antibodies directed to aspartyl-tRNA synthetase, a
purely cytoplasmic protein [15].2.4. Selection of HeLa cells that stably expressed human mitochondrial
LysRS fused to GFP
The cDNAs encoding the premitochondrial species of human LysRS
was introduced between the BglII and EcoRI sites of the pEGFP-N1
vector (BD Biosciences) to give pEGFP/pmKRS. HeLa cells were
grown in DMEM medium supplemented with 10% FCS, 2 mM gluta-
mine, 100 lg/ml of penicillin and streptomycin, and were transfected
with Eﬀectene (QIAGEN). Stable transformants were isolated by selec-
tion with G418.2.5. Confocal imaging
HeLa cells that stably expressed a pmLysRS-GFP fusion were
grown in RPMI medium supplemented with 10% FCS, 2 mM gluta-
mine, 100 lg/ml of penicillin and streptomycin. Cells were grown into
8-well Lab-Tek II chambers (Nalge Nunc International) and puriﬁed
Vpr was added to the culture medium where indicated. GFP ﬂuores-
cence was observed with a Leica TCS SP2 laser scanning confocal
microscope (Leica Microsystems, Mannheim, Germany). GFP was de-
tected using laser line 488 nm. The oil objective used was 100· (NA
1.40), giving a resolution of 140 nm in the x,y-plane and 240 nm along
the z-axis.Fig. 1. Puriﬁcation and characterization of recombinant Vpr. (a) The
puriﬁed GST-Vpr recombinant protein was analyzed by SDS–PAGE
and stained with Coomassie blue. The lower polypeptide corresponds
to a degradation product. Molecular masses (in kDa) of markers are
indicated on the right. (b) Activity of LysRS in the tRNA aminoa-
cylation reaction after preincubation with increasing amounts of GST-
Vpr.2.6. Aminoacylation assay of human LysRS
Initial rates of tRNA aminoacylation were measured at 25 C in
0.1 ml of 20 mM Imidazole-HCl buﬀer (pH 7.5), 100 mM KCl,
0.5 mM DTT, 12 mM MgCl2, 2 mM ATP, 180 lM
14C-labeled lysine
(NEN; 16.66 Ci/mol) and saturating amounts of tRNA [20]. Human
tRNALys3 expressed in E. coli (lysine acceptance of 600 pmol/A260)
was used as tRNA substrate. LysRS (0.25 lM) was preincubated at
25 C for 30 min in the presence of GST-Vpr (0.15–10 lM) in
20 mM Tris–HCl (pH 7.5), 100 mM NaCl, 10% glycerol and 1 mM
DTT. The incubation mixture was diluted (150-fold) in 10 mM Tris–
HCl (pH 7.5), 10 mM 2-mercaptoethanol, containing bovine serum
albumin at 4 mg/ml and immediately processed in the aminoacylation
reaction.3. Results
3.1. Vpr does not interact with LysRS
The viral protein Vpr has been reported to interact with the
cytoplasmic species of LysRS and to inhibit its tRNA amino-
acylation activity [17]. The GST-Vpr fusion protein was ex-
pressed in E. coli and puriﬁed to homogeneity (Fig. 1a). Its
isolation as a soluble and homogeneous protein required the
presence of detergents (NP40 and DOC) in the buﬀers all along
the puriﬁcation procedure. The recombinant cytoplasmic form
of human LysRS was incubated with increasing amounts of
Vpr, and its activity was determined by the tRNALys aminoa-
cylation reaction. When increasing concentrations of Vpr were
added to LysRS, the aminoacylation capacity of the enzyme
was not signiﬁcantly aﬀected (Fig. 1b). In particular, no inhi-
bition of LysRS activity was observed even in the presence
of a 40-fold molar excess of Vpr. To test the possibility of a
protein–protein interaction between Vpr and LysRS, the
GST-Vpr fusion protein was immobilized on a glutathione Se-
pharose column and incubated with LysRS. LysRS was re-
tained on the column, but this interaction was inhibited by
adding BSA at 2 mg/ml in the binding buﬀer (results not
shown). Thus the association of LysRS with Vpr is not highly
speciﬁc.
3.2. Eﬀect of Vpr-induced apoptosis on cellular LysRS
Vpr is able to induce apoptosis and to cause the release of
mitochondrial proteins [6,8,9]. As a control experiment of
the biological activity of Vpr, we ﬁrst tested whether our puri-
ﬁed recombinant protein produced in E. coli could inhibit cell
growth. U937 cells, a human promonocytic cell line, were incu-
bated in complete RPMI medium with the addition of Vpr at
diﬀerent concentrations (Fig. 2). A signiﬁcant growth inhibi-
tion was observed in the presence of 10 nM or 100 nM Vpr.
After 5 days of incubation in the presence of 10 or 100 nM
Vpr, most of the cells displayed a typical apoptotic morphol-
ogy, characterized by nuclear chromatin condensation.
The time-course of Vpr-induced apoptosis was followed
after addition of puriﬁed recombinant Vpr, at a concentration
of 17 nM, to the culture medium of U937 cells (Fig. 3). Cell
growth was inhibited and stopped after 43 h of incubation.
Fig. 2. Cell growth inhibition induced by Vpr. U937 cells were grown
in complete RPMI medium containing 10% FCS, in the absence (0) or
in the presence of 1 nM, 10 nM or 100 nM Vpr. The initial cell density
was 10 · 104 cells/ml. After 5 days of incubation at 37 C, cells were
counted.
Fig. 3. Vpr-induced apoptosis on human U937 cells. After addition of
puriﬁed recombinant Vpr (17 nM) and at the times indicated, cells
were counted (4), stained with the vital dye trypan blue (m), the
number of apoptotic cells was assessed by counting cells displaying a
typical apoptotic morphology (j), and cell survival was estimated by
the MTT assay ().
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sponding to necrotic cells, remained negligible during the ﬁrst
50 h of incubation. In the mean time, consistent with a pro-
gression of apoptosis, the viability of the cells, measured by
the MTT assay, decreased after 25 h of exposure to Vpr. The
appearance of an apoptotic morphology could be observed
after 43 h. Concomitantly, cleavage of poly-ADP ribose poly-
merase (PARP), a landmark of apoptosis, occurred after 43 hFig. 4. Apoptosis induced by Vpr. U937 cells were incubated for 17, 25, 43, 49
Western blot analysis with anti-PARP and anti-LysRS antibodies (a), or wit
p43(ARF). (c) Mitochondrial extracts were probed with anti-mitochondrial
LysRS and mito-p43 recovered in the mitochondria of U937 cells subjected toof addition of Vpr (Fig. 4a). In the mean time, the cellular con-
tent of LysRS was not signiﬁcantly aﬀected and no proteolytic
derivative could be observed (Fig. 4a), as deduced from a Wes-
tern blot analysis performed with anti-KRS antibodies that
cross-react with the cytoplasmic and mitochondrial species of
LysRS. The cytoplasmic species of LysRS is a component of
a multi-aminoacyl-tRNA synthetase complex (MARS) [21].or 64 h in the presence of 17 nM of Vpr. Total extracts were probed by
h anti-p43 antibodies (b). M, marker containing recombinant p43 and
LysRS antibodies or with anti-p43 antibodies. The fraction of mito-
Vpr treatment was quantiﬁed with a FUJI LAS-3000 imaging system.
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p43 that is known to be cleaved into p43(ARF) (ARF = apop-
tosis-released factor) during apoptosis [22]. Accordingly, anti-
bodies directed to human p43 showed that this component of
MARS was almost completely converted into p43(ARF) after
64 h of incubation of U937 cells in the presence of Vpr
(Fig. 4b).
The cytoplasmic form of LysRS, a component of MARS, is
the major cellular source of LysRS. The mitochondrial species
of LysRS, encoded by the same gene, accounts for about 5–
10% of total LysRS [15]. Thus, blotting with anti-KRS anti-
bodies (Fig. 4a) did not distinguish between the two forms of
LysRS that display similar electrophoretic mobilities. Because
cyto-LysRS is the major species, this result clearly showed that
cyto-LysRS is not degraded after onset of apoptosis, but did
not provide any compelling information concerning mito-
LysRS. To gain more insight into mito-LysRS, the extent of
LysRS present in the mitochondria of U937 cells subjected
to Vpr treatment was determined after subcellular fraction-
ation of U937 cell extracts (Fig. 4c). When anti-mKRS anti-
bodies were used, directed to a synthetic peptide speciﬁc of
the mitochondrial species of LysRS [15], the mitochondrial
content of mito-LysRS was signiﬁcantly decreased (4-fold)
after 49 h of Vpr treatment. (Fig. 4c). Mito-LysRS was not
found to be degraded during apoptosis. A fraction of the
p43 component of MARS is also recovered in the mitochon-
dria of human cells (Shalak and Mirande, unpublished results).
The level of mito-p43 was not altered during incubation of
U937 cells with Vpr (Fig. 4c) and, by contrast with the cyto-
plasmic fraction (Fig. 4b), was not processed into p43(ARF).
These results suggested that the steady-state level of mito-
LysRS in the mitochondrial compartment decreased after
induction of apoptosis by addition of extracellular Vpr.
3.3. Mitochondrial localization of LysRS is aﬀected by the viral
protein Vpr
To explore the possible relocalization of mito-LysRS in Vpr-
treated cells, we constructed a cell line that stably expressed theFig. 5. Eﬀect of Vpr on the extent of LysRS present in the mitochondrial com
transformants were isolated by selection with G418. The stable cell line was g
Vpr at 17 nM (238 pg/ml) for 24 or 48 h and analyzed by confocal microscop
parameters, including laser excitation intensity and PMT detector sensitivitymitochondrial precursor of LysRS (premito-LysRS) fused to
GFP. As observed previously upon transient transfection of
HeLa cells [15,23], the GFP-fusion protein was localized in
the mitochondria of the stable cell line isolated after transfec-
tion of HeLa cells (Fig. 5). After addition of Vpr (17 nM) to
the culture medium, the extent of mitochondria labeling de-
creased after 24 h of incubation and almost disappeared after
48 h (Fig. 5a). In the absence of Vpr, the subcellular staining
obtained with the premitoLysRS-GFP fusion is characteristic
of an extended mitochondrial network (Fig. 5b). Twenty four
hours after addition of Vpr, the labeling is more punctuate,
showing a restricted mitochondrial network. After 48 h, the
large decrease of mitochondria labeling was accompanied by
the appearance of a faint ﬂuorescence in the cytoplasm, sug-
gesting the presence of the mitochondrial LysRS-GFP fusion
in the cytoplasm (Fig. 5b).4. Discussion
The viral protein Vpr is an apoptogenic protein that acts on
the permeability transition pore complex and induces dissipa-
tion of the inner mitochondrial transmembrane potential, the
release of cytochrome c and apoptosis-inducing factor [5,6].
The apoptogenic properties of HIV-1 Vpr have been observed
after incubation of isolated mitochondria with Vpr [6], after
expression of Vpr in transfected cells [5,8,9], or after incuba-
tion of culture cells with Vpr [6,12]. The latter eﬀect could be
ascribed to the transducing capabilities of HIV-1 Vpr [12,13].
However, the extent of membrane permeabilization, and the
possibility that all or only a limited number of mitochondrial
proteins may be released in the cytoplasm of Vpr-treated cells
is not known. Here, we reported that addition of puriﬁed re-
combinant Vpr at very low concentrations (10 nM, that is
140 pg/ml) to the culture medium of human U937 cells induces
cell growth arrest and triggers apoptosis. Poly-ADP ribose
polymerase and the p43 component of the MARS complex
were cleaved after 43 h of Vpr treatment, but neither the cyto-partment. HeLa cells were transfected with pEGFP/pmKRS and stable
rown in Lab-Tek chambers in the absence (Vpr) or in the presence of
y at low (zoom = 1) (a) or high (zoom = 2) (b) magniﬁcation. Imaging
, were identical for the three analyses.
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cessed. However, when puriﬁed Vpr was added to the culture
medium of HeLa cells that stably expressed the premitochond-
rial form of LysRS fused to GFP, the extent of mitochondria
labeling was severely decreased after 48 h of Vpr-exposure.
These results suggest that Vpr is able to induce relocalization
of the mitochondrial form of LysRS. Because we observed that
Vpr does not bind speciﬁcally to LysRS, the eﬀect of Vpr is
most certainly not due to a direct protein–protein interaction
with LysRS but is likely to involve an indirect eﬀect on the
mitochondrial localization of LysRS.
The human KARS gene encodes both the cytoplasmic and
mitochondrial species of LysRS via a mechanism of alternative
splicing (Fig. 6) [15,23]. In the cytoplasm, the two mRNAs are
translated to give the cytoplasmic species (cLysRS) and the
precursor of the mitochondrial form of LysRS (pmLysRS).
The matured form, mLysRS, is produced during importation
into the mitochondria by cleavage of the N-terminal targeting
sequence of pmLysRS. Only the mitochondrial species of
LysRS (pmLysRS and/or mLysRS) has been identiﬁed in the
HIV-1 virions [15]. The mechanism of selection of LysRS for
packaging into HIV-1 particles is not well understood, but
proteins of HIV-1 (pHIV-1; Fig. 6), including the two viral
proteins Gag and Gag-Pol [16], are believed to be involved
in the packaging process. Association of cLysRS with the
other components of MARS [21] may preclude its interaction
with a protein of HIV-1 and its targeting to the virions. The
absence in cLysRS of the mitochondria-speciﬁc N-terminal se-
quences characteristic of pmLysRS may explain the lack of
speciﬁcity observed in vitro for the interaction between
cLysRS and Gag [24]. Concerning the packaging of the mito-
chondrial form of LysRS, two pathways for virion targeting
may be envisioned.Fig. 6. Possible routes of uptake of mitochondrial LysRS. The two
mRNAs encoding cyto-and premito-LysRS are produced from a single
gene, KARS. The cytoplasmic form of LysRS (cLysRS) associates
with the 10 other components of MARS, the multi-aminoacyl-tRNA
synthetase complex. The precursor of the mitochondrial species of
LysRS (pmLysRS) is cleaved upon import into the mitochondria to
give the matured mitochondrial species of LysRS (mLysRS). The
nature of the mitochondrial species of LysRS (pmLysRS or mLysRS)
that is packaged into the virion, and of the proteins of HIV-1 (pHIV-1)
involved in this process, are not known. See text for details.In the ﬁrst of these scenarios, the premitochondrial species
of LysRS would be targeted to the virion. Interaction of
pmLysRS with pHIV-1 would occur before its mitochondrial
uptake. The ﬁnding that the steady-state level of mitochondrial
LysRS decreases following Vpr treatment is consistent with
this hypothesis. General inhibition of mitochondrial import,
and especially of pmLysRS, by Vpr, a protein known to per-
turb the integrity of the mitochondrial membranes [6], would
lead to a gradual depletion of LysRS in the mitochondrial
compartment, as degradation of mLysRS proceeds according
to its half-life time. The pmLysRS species held in the cyto-
plasm could associate with cytoplasmic tRNALys, including
tRNA
Lys
3 , and with a pHIV-1 that would target the ternary
complex pHIV-1:pmLysRS:tRNALys to the virions. An alter-
native possibility would be that mLysRS is released form the
mitochondria following Vpr-treatment, associates with cyto-
plasmic tRNA and is directed to the virions. Whether
pmLysRS and mLysRS or a single of these two LysRS species
is the source of viral LysRS remains to be clearly established.
Our results suggest that Vpr is a key factor in this process.
Acknowledgements: We thank Franc¸oise Bachelerie (Institut Pasteur,
Paris) for the gift of the pGEX/Vpr plasmid and Uwe Tessmer (Hein-
rich-Pette-Institute, Hamburg, Germany) for the anti-Vpr antibodies.
We also thank Spencer Brown and Susanne Bolte for access to the con-
focal microscope facility (ISV, Gif-sur-Yvette, France). This work was
supported by grants from the ‘‘Centre National de la Recherche Scien-
tiﬁque’’ (CNRS), the ‘‘Agence Nationale de Recherches sur le SIDA’’
(ANRS), the ‘‘Association pour la Recherche sur le Cancer’’ (ARC)
and ‘‘La ligue’’. M.K. was the recipient of postdoctoral fellowships
of ‘‘Fondation pour la Recherche Me´dicale’’ and ‘‘Association pour
la Recherche sur le Cancer’’ and V.S. was the recipient of postdoctoral
fellowship of ‘‘Agence Nationale de Recherches sur le SIDA’’.References
[1] Sherman, M.P., de Noronha, C.M., Heusch, M.I., Greene, S.
and Greene, W.C. (2001) Nucleocytoplasmic shuttling by
human immunodeﬁciency virus type 1 Vpr. J. Virol. 75, 1522–
1532.
[2] Muthumani, K., Choo, A.Y., Premkumar, A., Hwang, D.S.,
Thieu, K.P., Desai, B.M. and Weiner, D.B. (2005) Human
immunodeﬁciency virus type 1 (HIV-1) Vpr-regulated cell death:
insights into mechanism. Cell Death Diﬀer. 12 (Suppl. 1), 962–
970.
[3] Le Rouzic, E. and Benichou, S. (2005) The Vpr protein from HIV-
1: distinct roles along the viral life cycle. Retrovirology 2, 11.
[4] Paxton, W., Connor, R.I. and Landau, N.R. (1993) Incorporation
of Vpr into human immunodeﬁciency virus type 1 virions:
requirement for the p6 region of gag and mutational analysis. J.
Virol. 67, 7229–7237.
[5] Stewart, S.A., Poon, B., Song, J.Y. and Chen, I.S. (2000) Human
immunodeﬁciency virus type 1 vpr induces apoptosis through
caspase activation. J. Virol. 74, 3105–3111.
[6] Jacotot, E., Ravagnan, L., Loeﬄer, M., Ferri, K.F., Vieira, H.L.,
Zamzami, N., Costantini, P., Druillennec, S., Hoebeke, J., Briand,
J.P., Irinopoulou, T., Daugas, E., Susin, S.A., Cointe, D., Xie,
Z.H., Reed, J.C., Roques, B.P. and Kroemer, G. (2000) The HIV-
1 viral protein R induces apoptosis via a direct eﬀect on the
mitochondrial permeability transition pore. J. Exp. Med. 191, 33–
45.
[7] Somasundaran, M., Sharkey, M., Brichacek, B., Luzuriaga, K.,
Emerman, M., Sullivan, J.L. and Stevenson, M. (2002) Evidence
for a cytopathogenicity determinant in HIV-1 Vpr. Proc. Natl
Acad. Sci. USA 99, 9503–9508.
[8] Muthumani, K., Hwang, D.S., Desai, B.M., Zhang, D., Dayes,
N., Green, D.R. and Weiner, D.B. (2002) HIV-1 Vpr induces
apoptosis through caspase 9 in T cells and peripheral blood
mononuclear cells. J. Biol. Chem. 277, 37820–37831.
3110 M. Kaminska et al. / FEBS Letters 581 (2007) 3105–3110[9] Sakai, K., Dimas, J. and Lenardo, M.J. (2006) The Vif and Vpr
accessory proteins independently cause HIV-1 induced T cell
cytopathocity and cell cycle arrest. Proc. Natl Acad. Sci. USA
103, 3369–3374.
[10] Jacotot, E., Ferri, K.F., El Hamel, C., Brenner, C., Druillennec,
S., Hoebeke, J., Rustin, P., Metivier, D., Lenoir, C., Geuskens,
M., Vieira, H.L., Loeﬄer, M., Belzacq, A.S., Briand, J.P.,
Zamzami, N., Edelman, L., Xie, Z.H., Reed, J.C., Roques, B.P.
and Kroemer, G. (2001) Control of mitochondrial membrane
permeabilization by adenine nucleotide translocator interacting
with HIV-1 viral protein R and Bcl-2. J. Exp. Med. 193, 509–520.
[11] Levy, D.N., Refaeli, Y. and Weiner, D.B. (1995) Extracellular
Vpr protein increases cellular permissiveness to human immuno-
deﬁciency virus replication and reactivates virus from latency. J.
Virol. 69, 1243–1252.
[12] Henklein, P., Bruns, K., Sherman, M.P., Tessmer, U., Licha, K.,
Kopp, J., de Noronha, C.M., Greene, W.C., Wray, V. and
Schubert, U. (2000) Functional and structural characterization of
synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus,
and induces G2 cell cycle arrest. J. Biol. Chem. 275, 32016–32026.
[13] Sherman, M.P., Schubert, U., Williams, S.A., de Noronha, C.M.,
Kreisberg, J.F., Henklein, P. and Greene, W.C. (2002) HIV-1 Vpr
displays natural protein-transducing properties: implications for
viral pathogenesis. Virology 302, 95–105.
[14] Jiang, M., Mak, J., Ladha, A., Cohen, E., Klein, M., Rovinski, B.
and Kleiman, L. (1993) Identiﬁcation of tRNAs incorporated into
wild-type and mutant human immunodeﬁciency virus type-1. J.
Virol. 67, 3246–3253.
[15] Kaminska, M., Shalak, V., Francin, M. and Mirande, M. (2007)
Viral hijacking of mitochondrial lysyl-tRNA synthetase. J. Virol.
81, 68–73.
[16] Javanbakht, H., Halwani, R., Cen, S., Saadatmand, J., Musier-
Forsyth, K., Gottlinger, H. and Kleiman, L. (2003) The interac-
tion between HIV-1 Gag and human lysyl-tRNA synthetase
during viral assembly. J. Biol. Chem. 278, 27644–27651.[17] Stark, L.A. and Hay, R.T. (1998) Human immunodeﬁciency virus
type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA
synthetase: implications for priming of HIV-1 reverse transcrip-
tion. J. Virol. 72, 3037–3044.
[18] Mirande, M., Cirakoglu, B. and Waller, J.P. (1982) Macromo-
lecular complexes from sheep and rabbit containing seven
aminoacyl-tRNA synthetases. III. Assignment of aminoacyl-
tRNA synthetase activities to the polypeptide components of
the complexes. J. Biol. Chem. 257, 11056–11063.
[19] Shalak, V., Kaminska, M., Mitnacht-Kraus, R., Vandenabeele,
P., Clauss, M. and Mirande, M. (2001) The EMAPII cytokine is
released from the mammalian multisynthetase complex after
cleavage of its p43/proEMAPII component. J. Biol. Chem. 276,
23769–23776.
[20] Francin, M., Kaminska, M., Kerjan, P. and Mirande, M. (2002)
The N-terminal domain of mammalian lysyl-tRNA synthetase
is a functional tRNA-binding domain. J. Biol. Chem. 277, 1762–
1769.
[21] Mirande, M. (1991) Aminoacyl-tRNA synthetase family from
prokaryotes and eukaryotes: structural domains and their impli-
cations. Prog. Nucl. Acid Res. Mol. Biol. 40, 95–142.
[22] Shalak, V., Guigou, L., Kaminska, M., Wautier, M.P., Wautier,
J.L. and Mirande, M. (2007) Characterization of p43(ARF), a
derivative of the p43 component of multiaminoacyl-tRNA
synthetase complex released during apoptosis. J. Biol. Chem.
282, 10935–10943.
[23] Tolkunova, E., Park, H., Xia, J., King, M.P. and Davidson, E.
(2000) The human lysyl-tRNA synthetase gene encodes both the
cytoplasmic and mitochondrial enzymes by means of an unusual
alternative splicing of the primary transcript. J. Biol. Chem. 275,
35063–35069.
[24] Kovaleski, B.J., Kennedy, R., Hong, M.K., Datta, S.A., Kleiman,
L., Rein, A. and Musier-Forsyth, K. (2006) In vitro character-
ization of the interaction between HIV-1 Gag and human lysyl-
tRNA synthetase. J. Biol. Chem. 281, 19449–19456.
